Login / Signup

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.

Huijing WangTing LiFangfang SunZhe LiuDanting ZhangXiangyu TengLaurence MorelXiaodong WangShuang Ye
Published in: RMD open (2022)
ChiCTR1800015030.
Keyphrases
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • open label
  • double blind
  • placebo controlled